


### Meeting of the Interagency Pain Research Coordinating Committee

December 3<sup>rd</sup>, 2015

Porter Building, Rm 610 NIH Main Campus



# Tmem100: A novel pain modulator, and potential therapeutic target



HEK293T

Scrambled T100-Mut T100-WT

1hr

Paclitaxel

Baseline Dav7 Dav7+T100-Mut

Von Frey

Baseline

C <sub>25-</sub>

Besponse Hesponse Hes

1.5

Threshold(g)

0.0

G

1.5

Threshold(a)

0.0

~ 5

MO-induced pain & hyperalgesia

CAP

DRG neurons

Scrambled

MO

Acute

Scrambled T100-Mut

CAP

Scrambled T100-Mut

В

% Response/IB4

D

Time licking(s)

F

100

Time licking(s)

25

20

15

10

5

- TRPV1 and TRPA1 are key pain transducers
- In vivo, Tmem100 loosens the physical association between TRPV1 and TRPA1, allowing greater TRPA1 responsiveness and increased pain
- Mutating the C terminus of Tmem100 tightens the association between TRPV1 and TRPA1, decreasing TRPA1 responsiveness
- Tmem100–/– animals show reductions in pain behavior following inflammatory injury
- Injection of a peptide consisting of the mutated C terminus of Tmem100 partially relieves pain behaviors in an animal model
- Tmem100 is a strong viable target for the alleviation of acute mechanical pain

Weng et al. Neuron Feb 2015




Interagency Pain Research Coordinating Committee

# Implantable wireless devices can control pain signals

- Optogenetics allows rapid, temporally specific control of neuronal activity by targeted expression and activation of light-sensitive proteins in neurons
- This paper represents a technological leap in developing soft, stretchable, fully implantable miniaturized systems for wireless optogenetics
- Wireless activation of channelrhodopsin-2 expressed in nociceptive pathways resulted in spontaneous pain behaviors and place aversion
- These implantable devices can activate

   and, in theory, block pain signals in
  the peripheral nervous system before
  those signals reach the brain


Park et al. Nature Biotechnology Nov 2015





## Sexual dimorphism in microglial contribution to pain

- Basic science research clearly shows that microglia-to-neuron signaling is essential for chronic pain hypersensitivity but most of these studies have used male animals
- However, many pain conditions are more common in women than men
- This study examined whether sex affects microglial involvement in nerve injury pain
- The authors found that microglia are not required for nerve injury-induced mechanical pain in female mice
- Adaptive immune cells (T cells) are key instead
- Distinct strategies targeting neuroimmune signaling may be required for the treatment of chronic pain in men versus women



Interagency Pain Research Coordinating Committee

Sorge *et al*. Nature Neuroscience Aug 2015

### *The National Academies of* SCIENCES • ENGINEERING • MEDICINE


#### FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS Board on Health Sciences Policy

November 10, 2015


Institute of Medicine

Explore the application of the Accelerating Medicines Partnership (AMP) approach to pain. Discuss challenges and identify what would be needed to make this therapeutic domain a good candidate for this approach.

- Biomarker Development
  - Brain Imaging
  - Peripheral biomarkers



• Use of Data Registries





### Discussion of AMP for Pain

### **Topics discussed:**

- Development of biomarkers for pain
- Identifying responders v. non-responders to minimize risk of clinical trial failure
- Understanding/circumventing the 'placebo effect' in clinical trials
- Considering pain duration as a target with the goal of reducing the duration of acute pain as well as the transition to chronic pain
- IPRCC Use of Federal Pain Research Strategy to identify potential research areas that are ideal for an AMP

